CARCINOMA DELLA PROSTATA
description
Transcript of CARCINOMA DELLA PROSTATA
![Page 1: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/1.jpg)
CARCINOMA DELLA PROSTATA
![Page 2: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/2.jpg)
PROSTATE CANCERPROSTATE CANCER
Prostate Anatomy
![Page 3: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/3.jpg)
Prostate cancer is a disease predominantly of the older male population. Autopsy series have indicated that 15% to 30% of men older than the age 50 years have histologic
evidence of prostate cancer
![Page 4: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/4.jpg)
PROSTATE CANCER DEATHS BY AGEPROSTATE CANCER DEATHS BY AGE
![Page 5: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/5.jpg)
![Page 6: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/6.jpg)
![Page 7: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/7.jpg)
![Page 8: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/8.jpg)
![Page 9: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/9.jpg)
Risk Factors for Prostate CancerRisk Factors for Prostate Cancer• Age – Found mainly in men over age 55. Average age
of diagnosis is 70• Family History – Men’s risk is higher if father or brother
is diagnosed before the age of 60• Race – Prostate cancer is found more often in African
American men then White men. It is less common in Asian and American Indian men
• Dietary factors – Evidence suggests that a diet high in fat may increase the risk of prostate cancer and diets high in fruits and vegetables decrease the risk
![Page 10: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/10.jpg)
Risk for DevelopingRisk for Developing Prostate Cancer Prostate Cancer
![Page 11: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/11.jpg)
Genetic alterations associated with progression of prostate cancer
![Page 12: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/12.jpg)
Hypothalamus pituitary testicular axis
![Page 13: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/13.jpg)
Detailed schematic: Lateral sectionof a normal prostate
![Page 14: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/14.jpg)
PROSTATE CANCERPROSTATE CANCER
Stage A : Deep tumor: may not be detected by digital-rectal exam
Stage B: Tumor may be detected by DRE or ultrasound
Stage C: Spread to surrounding tissue Stage D: Metastasis to bone
and lymph nodes
![Page 15: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/15.jpg)
![Page 16: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/16.jpg)
The Gleason grading system is used to evaluate or grade
prostate cancer cells obtained by needle
biopsy. The cells are assigned a number between 1 and 5
nearly normal cells are grade 1, and the most abnormal are grade 5. The scores of the two
most common cell patterns are added
together. Gleason scores range
from 2 to 10. The higher the grade, the more
aggressive the cancer.
The Gleason scoring system for prostate cancer.
![Page 17: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/17.jpg)
![Page 18: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/18.jpg)
Prostatic Intraepithelial Neoplasia• 85% carcinomas have
associated PIN• High grade PIN has 30-
50% risk of CA on subsequent biopsies cf 13% in controls
• PIN does not cause elevated PSA
• Atypical foci in 3-5% of biopsies, 50% risk of cancer on repeat biopsy
![Page 19: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/19.jpg)
Symptoms of Prostate CancerSymptoms of Prostate Cancer• Frequent urination• Inability to urinate• Trouble starting and stopping urination• Blood in the urine or semen• Painful ejaculation• Painful or burning urination
![Page 20: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/20.jpg)
Screening for Prostate CancerScreening for Prostate Cancer
• Prostate-Specific Antigen Blood Test (PSA) – Measures substance made by the prostate gland
• Digital Rectal Exam (DRE) – Physical exam of the Prostate Gland
• Transrectal Ultrasound (TRUS) – Uses sound waves to make an image of the prostate on a video screen
![Page 21: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/21.jpg)
Screening … For & AgainstScreening … For & Against• Organ confined prostate
cancer is curable
• Advanced prostate cancer is incurable
• Screening offers earlier diagnosis
• Early detection is our only hope for mortality reduction
• More men die with Prostate cancer than of it
• PSA test not accurate enough
• Biopsy and treatment may cause morbidity
• No trial to show mortality reduction
![Page 22: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/22.jpg)
![Page 23: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/23.jpg)
![Page 24: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/24.jpg)
Factors Increasing PSA• Cycling• Prostate massage• Cystoscopy• Ejaculation • Prostate biopsy• Transrectal Ultrasound• Prostate disease
![Page 25: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/25.jpg)
Percentage risk of CaP
PSA < 4 (%)
4-10 (%)
>10 (%)
DRE neg 9 20 31
DRE pos 17 45 77
![Page 26: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/26.jpg)
Screening - Improving the PSAScreening - Improving the PSA
• PSA Velocity > 0.75 ng/ml/yr
• PSA Density
• Age adjusted PSA
• Molecular forms- free / total PSA
![Page 27: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/27.jpg)
PSA IsoformsPSA Isoforms
• Free and complexed PSA - ACT
• FREE / TOTAL ratio < 10% suggestive
• Complex now measurable
![Page 28: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/28.jpg)
Digital Rectal Exam for Prostate Tumors
![Page 29: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/29.jpg)
Transrectal ultrasound-guided biopsy of the prostate
![Page 30: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/30.jpg)
![Page 31: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/31.jpg)
Management AlternativesManagement Alternatives• Expectant -- Watchful Waiting
• Radical Prostatectomy
• Radiation Therapy -- EBRT, 3D - CRT,Brachytherapy: HDR,
Seed• Hormonal -- Mono Rx, MAB
• Combination
![Page 32: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/32.jpg)
Trans-urethral Resection
![Page 34: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/34.jpg)
Prostate CancerProstate CancerTreatment ParadigmsTreatment Paradigms
ClinicallyLocalized
HormoneRefractory
Local treatment Endocrine Chemotherapy
Relapsedand
Newly diagnosed M+
![Page 35: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/35.jpg)
Prostate Cancer Treatment Background
• 50% fail after local treatment
• 10-15% have distant metastasis at presentation
• Virtually all progress after endocrine treatment
• Chemotherapy used for symptomatic control– No survival advantage in phase-III trials
![Page 36: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/36.jpg)
Endocrine control of prostate cancer
![Page 37: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/37.jpg)
Strategies for Androgen Deprivation
LHRH = Luteinizing hormone-releasing hormone
5 R = 5-alpha reductase.
LH = Luteinizing hormone
AR = Androgen receptor
T = Testosterone
DHT = Dihydrotestosterone.
![Page 38: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/38.jpg)
Types of Androgen Deprivation
Monotherapy Bilateral orchiectomy Medical castration Estrogen LHRH agonist: leuprolide, goserelin Steroidal antiandrogens Megesterol acetate Cyproterone acetate Nonsteroidal antiandrogens Flutamide Bicalutamide NilutamidePrimary gonadal suppression + antiandrogen
![Page 39: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/39.jpg)
Side Effects of Androgen Deprivation
Impotence: 75%-100%Hot flashes: 60%Accelerated osteoporosis, muscle massGI upset, weight gain, leg edema, gynecomastiaUnknown effects: lipids, cognitive function, other biologic systemsCost
![Page 40: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/40.jpg)
Adjuvant trials. SWOG 9921: adjuvant androgen deprivation versus mitoxantrone plus prednisone plus androgen deprivation in selected high-risk prostate cancer patients following radical prostatectomy, phase III. Prior neoadjuvant therapy is
permitted if the duration is 4 months or less and if clinical criteria (PSA 15 ng/mL or biopsy GS 7 or PSA 10 ng/mL and GS 6) are satisfied prior to surgery.
![Page 41: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/41.jpg)
Adjuvant trials. RTOG 99-02: phase III protocol of androgen suppression (AS) and radiation therapy (RT) versus AS and RT followed by chemotherapy with paclitaxel,
estramustine, and etoposide for localized high-risk prostate cancer.
![Page 42: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/42.jpg)
Adjuvant hormonal therapy. Survival improvements were noted only in one trial conducted by the European Organization for Research and Treatment of Cancer
with the use of adjuvant hormonal therapy. (Adapted from Bolla et al.)
![Page 43: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/43.jpg)
Adjuvant hormones. Adjuvant hormones after radical prostatectomy have demonstrated survival enhancement in patients with pathologically positive
lymph nodes. (Adapted from Messing et al.
![Page 44: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/44.jpg)
SWOG Intergroup 0162 trial of continuous versus intermittent androgen deprivation
![Page 45: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/45.jpg)
Hormone-independent prostate cancer. The development of hormonal escape is depicted. Despite a high initial response rate to androgen deprivation, essentially all men
will fail and progress to androgen independence and ultimately hormone refractory status. Treatment for patients with hormone-refractory prostate cancer must be tailored
individually, and take into account the need to maintain quality of life in this terminal stage of the disease. Antiandrogen withdrawal, second-line hormonal therapy, palliative
supportive care measures including radiation therapy (external or systemic) and pain control, and chemotherapy are all valid options.
![Page 46: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/46.jpg)
Mitoxantrone + Steroids Versus Steroids Alone
ChemotherapyPatients, n RR MS
Tannock et al. [33]
Pred 81 P 12% P 18 wk
Mitox + pred 80 P 29% P 43 wk
Kantoff et al. [34]
HC 121 PSA 14% 12.3 mo
HC+mitox 121 PSA 19% 12.6 mo
Table of randomized chemotherapy trials in metastatic disease. Although chemotherapy has not demonstrated an impact on survival yet, the use of mitoxantrone
and steroids has, however, demonstrated a significant palliative effect in randomized trials
![Page 47: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/47.jpg)
SWOG trial of chemotherapy in metastatic disease. SWOG Intergroup 9916 randomized phase III study of docetaxel + estramustine versus
mitoxantrone + prednisone in patients with hormone-refractory prostate cancer; 620 patients must be entered to detect a 33% survival difference. Future directions include exploring biologic therapies such as epithelial
growth factor receptor inhibitors and antiangiogenesis strategies.
![Page 48: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/48.jpg)
Combined Androgen Deprivation Compared with Monotherapy in Advanced Prostate Cancer
AuthorTreatment Patients, n mPFS MS P value
Crawford et al. Leup+plac 300 13.9 28.3 0.03 (PFS)
Leup+flut 303 16.5 35.6 0.03 (OS)
Keuppens et al.
Orch 163 diff (s) 35 wks diff (ms) 7 m 0.009 (PFS)
Gos+flut 161 diff (o) 48 wks diff (c) 15 m 0.05 (OS)
Goserelin+flut arm superior in subjective and objective PFS, OS, and rate of cancer deaths.
Tyrrell et al. Gos 282 NR 37.7 0.08 (PFS)
Gos+flut 287 NR 42.4 0.14 (OS)
Hucher et al. Orch+Anan 545 NR NR 0.05 (PFS)
Orch+Plac 498 NR NR NS (OS)
Iversen et al. Orch 133 16.8 27.6 0.69 (RFS)
Gos+flut 129 16.5 22.7 0.49 (OS)
Eisenberger et al.
Orch+plac 687 18.6 29.9 0.26 (RFS)
Orch+flut 700 20.4 33.5 0.16 (OS
![Page 49: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/49.jpg)
Docetaxel in HRPC
• Multiple phase II studies • Responses in 45-82% (similar 95% CI duration)• Estramustine based RR higher but more toxic• Single agent data (weekly and every 3 wks)
consistently safe and effective• Superior to mitoxantrone + prednisone?
![Page 50: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/50.jpg)
TAX327TAX327Study DesignStudy Design
Stratification
Pain levelPPI ≥ 2 or AS ≥ 10
vs.PPI < 2 or AS < 10
KPS≤ 70 vs. ≥ 80
Docetaxel 75 mg/m2 q3 wks + Prednisone 5 mg bid
Mitoxantrone 12 mg/m2 q3 wks +
Prednisone 5 mg bid
RANDOMIZE
Docetaxel 30 mg/m2 wkly 5 of 6 wks +
Prednisone 5 mg bid
Treatment duration in all 3 arms = 30 wks
![Page 51: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/51.jpg)
Overall Survival
Mediansurvival Hazard
(mos) ratio P-value Combined: 18.2 0.83 0.03D 3 wkly: 18.9 0.76 0.009D wkly: 17.3 0.91 0.3Mitoxantrone 16.4 – –
Months0 6 12 18 24 30
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Docetaxel 3 wklyDocetaxel wklyMitoxantrone
Prob
abili
ty o
f Sur
vivi
ng
![Page 52: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/52.jpg)
TAX 327Docetaxel 3 Weekly
• Safe• Significantly improves: – Survival (18.9 vs 16.5 months)
24% reduction in the risk of death (95% CI 0.62-0.94, p=.009)
– PSA decline - 45% vs. 32%, p<.0005 – Pain response - 35% vs. 22%, p=.01 – Quality of life
![Page 53: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/53.jpg)
Prostate CancerProstate CancerTreatment ParadigmsTreatment Paradigms
ClinicallyLocalized
HormoneRefractory
Local treatmentDocetaxel + P
q3 wks
Improves survival
Endocrine
Relapsedand
Newly diagnosed M+
![Page 54: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/54.jpg)
Prostate CancerProstate CancerTreatment ParadigmsTreatment Paradigms
ClinicallyLocalized
HormoneRefractory
Local treatment Endocrine Docetaxel
Relapsedand
Newly diagnosed M+
?
?
![Page 55: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/55.jpg)
Prostate CancerProstate CancerTreatment ParadigmsTreatment Paradigms
ClinicallyLocalized
HormoneRefractory
Local treatment EndocrineMitoxantrone+Pfor symptoms
Relapsedand
Newly diagnosed M+
No SurvivalBenefit
![Page 56: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/56.jpg)
![Page 57: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/57.jpg)
![Page 58: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/58.jpg)
![Page 59: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/59.jpg)
![Page 60: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/60.jpg)
![Page 61: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/61.jpg)
![Page 62: CARCINOMA DELLA PROSTATA](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815d54550346895dcb5e71/html5/thumbnails/62.jpg)